Drew Moghanaki, Chief Medical Officer at Respirati and Professor and Chief of Thoracic Oncology at the Department of Radiation Oncology at David Geffen School of Medicine at UCLA, shared a post on X:
“Prof. Shankar Siva reminds us that SAFRON II was a ‘SABR in lieu of systemic therapy’ study for patients with lung metastases at SABRCAN 2025.”
More posts featuring Drew Moghanaki.
